The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.

The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.

Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.

The National Institute for Health and Care Excellence (NICE) recommends sotrovimab as an option for the treatment of patients with COVID-19 meeting specified clinical criteria and subject to a commercial arrangement agreed with the company. The National Health Service in England is legally required to make funding available for sotrovimab in line with NICE’s recommendations.

The Government secured stocks of sotrovimab on behalf of all nations in the United Kingdom. At current levels of use, driven by the existing access policies, there is sufficient stock held to last until the latter half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is available through normal commercial channels when this Government-owned stock is consumed.

Information on the proportion of hospitals with accident and emergency units that have supplies of Sotrovimab is not held.

Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.

NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.

The Department has well-established procedures to deal with medicine shortages and works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.

We are aware of a current supply issue with generic lamotrigine 5mg dispersible tablets for epilepsy. We have issued comprehensive management guidance to the National Health Service highlighting the availability of alternative products.

There have been issues with the supply of a limited number of hormone replacement therapy (HRT) products, primarily due to very sharp increases in demand, but the supply position for many of those products has improved considerably over the last year. Only one of the 23 Serious Shortage Protocols issued since April 2022 remains in place. We continue to engage with suppliers individually to address these issues and improve resilience in the short, medium and long term. We are also holding quarterly roundtables with manufacturers, wholesalers and community pharmacists to monitor progress and agree what more needs to be done to ensure supply is sufficient to meet demand. The eighth HRT supply roundtable is expected to be held in January 2024.

We are aware of disruptions to the global supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD). Some issues are now resolving. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. We are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.

Clinicians can prescribe any product on the National Health Service they consider necessary for the treatment of their patient unless it is listed in Schedules 1 or 2 to the NHS (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004. Ferric Maltol is not listed in Schedules 1 or 2; however, NHS guidance is that vitamins and minerals should not be routinely prescribed except for when a patient has a medically diagnosed deficiency. This includes those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Ferric Maltol, which may be used to treat iron deficiency, may therefore be prescribed to patients, including those in Chipping Barnet constituency, on that basis.

It is for the general practitioner or other responsible clinician to work with their patient and decide on the course of treatment, with the provision of the most clinically appropriate care for the individual always being the primary consideration. Clinicians are responsible for making prescribing decisions for their patients, considering best prescribing practice and the local commissioning decisions of their respective integrated care board.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE published guidance in August 2022 recommending both ceftazidime with avibactam and cefiderocol for treating severe drug-resistant gram-negative bacterial infections. This was as part of a project to test a new health technology evaluation process and payment model for antimicrobial products. NHS England has now issued contracts with the suppliers and cefiderocol and ceftazidime with avibactamare available for clinicians to prescribe in line with NICE’s recommendations.

The National Institute for Health and Care Excellence (NICE) is the independent body that guides the National Health Service on funding new medicines, based on clinical and cost-effectiveness.. The NHS is legally required to fund medicines recommended by NICE, usually within 3 months of final guidance.

NICE has recommended abiraterone for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone in line with NICE’s recommendations, ensuring access for eligible patients.

Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is currently considering a clinical policy proposal for abiraterone as a treatment option for potential use in specific cases. The proposal is due to be discussed later this month, with potential stakeholder testing by January 2024, if supported.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.

NICE published guidance in May 2022 recommending romosozumab for treating severe osteoporosis in people after menopause who are at high risk of fracture. Romosozumab is therefore available for clinicians to prescribe to NHS patients who meet the specified criteria, in line with NICE’s recommendations.

We have made no such assessment.

The Major Conditions Strategy will set out how we intend to tackle conditions that contribute most to morbidity and mortality across the population in England which include cancers; cardiovascular disease, including stroke and diabetes; chronic respiratory diseases; dementia; mental ill health; and musculoskeletal conditions.

Orkambi, Symkevi and Kaftrio are currently available as treatment options for eligible National Health Service patients with cystic fibrosis, under the terms of a commercial agreement reached between NHS England and the manufacturer. This agreement has enabled the collection of data to inform a full appraisal of these medicines by the National Institute for Health and Care Excellence (NICE), which is currently underway.

NICE published draft guidance on 3 November 2023 which does not recommend Orkambi, Symkevi and Kaftrio for the treatment of cystic fibrosis. The draft guidance is now subject to a public consultation and NICE’s committee will carefully consider all evidence as well as comments received during the consultation in developing its final guidance, which is expected to be published on 20 March 2024. Patients already receiving these treatments will have continued access following the publication of NICE’s final guidance, regardless of the outcome.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

It has not proved possible to reply to the hon. Member in the time available before prorogation.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.